Tomosada Yoshikawa
Direktor/Vorstandsmitglied bei KLAB INC.
Aktive Positionen von Tomosada Yoshikawa
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| KLAB INC. | Direktor/Vorstandsmitglied | 25.03.2018 | - |
| Independent Dir/Board Member | 25.03.2018 | - | |
| SUS CO.,LTD. | Direktor/Vorstandsmitglied | 01.12.2018 | - |
| Corporate Officer/Principal | 01.10.2018 | - | |
| Cross Reality Co., Ltd. | Direktor/Vorstandsmitglied | 01.09.2019 | - |
Karriereverlauf von Tomosada Yoshikawa
Ehemalige bekannte Positionen von Tomosada Yoshikawa
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| TELLA, INC. | Direktor/Vorstandsmitglied | 01.03.2018 | 27.03.2019 |
| Independent Dir/Board Member | 01.03.2018 | 27.03.2019 | |
| TAIKO PHARMACEUTICAL CO.,LTD. | Verwaltungsdirektor | 01.06.2009 | - |
| Direktor/Vorstandsmitglied | 01.06.2007 | - | |
| Finanzdirektor/CFO | 04.01.2011 | 01.06.2013 | |
| Investor Relations Kontakt | 01.06.2009 | - |
Ausbildung von Tomosada Yoshikawa
| Babson College | Masters Business Admin |
| Kwansei Gakuin University | Undergraduate Degree |
Statistik
International
| Japan | 7 |
| Vereinigte Staaten | 2 |
Operativ
| Director/Board Member | 5 |
| Independent Dir/Board Member | 2 |
| Chief Administrative Officer | 1 |
Sektoral
| Consumer Services | 3 |
| Health Technology | 3 |
| Technology Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| KLAB INC. | Technology Services |
| SUS CO.,LTD. | Commercial Services |
| TAIKO PHARMACEUTICAL CO.,LTD. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
| Cross Reality Co., Ltd. | |
tella, Inc.
 tella, Inc. BiotechnologyHealth Technology tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. It operates through the following segments: Cell Medicine, Medical Support, and Pharmaceuticals. The Cell Medicine segment provides cancer treatment technology and know-hows centered on dendritic cell vaccine therapy. The Medical Support segment manages contact research organization (CRO) business and offers genetic testing services. The Pharmaceuticals segment deals with the development of dendritic cell vaccine as a cancer treatment. The company was founded by Yuichiro Yazaki on June 24, 2004 and is headquartered in Tokyo, Japan. | Health Technology |
- Börse
- Insiders
- Tomosada Yoshikawa
- Erfahrung
